← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck Sharp & Dohme

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of unresectable or metastatic colorectal cancer with high microsatellite instability or deficient mismatch repair.

LAMPGEN ANALYSIS

Why it matters

Moved checkpoint inhibition into first-line treatment for a molecularly defined colorectal cancer population.

What research teams should watch

Get mismatch-repair or MSI results before first-line treatment selection and reconcile discordant results.

PRIMARY RECORDS

Sources